EULAR Offers Tips on Psoriasis Progression to PsA

Save

Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).

Time to Risk Stratify Methotrexate Lab Monitoring?

Save

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

Save

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

EULAR 2023 recommendation for imaging in large vessel vasculitis

Save

Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. At EULAR 2023, recommendations for imaging modalities for large vessel vasculitis were discussed. These were evidence-based recommendations adapted for practicality in clinical use.  

EULAR 2023 Notes from Milan (6.09.2023)

Save

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Combining a Tyk2 inhibitor with a JAKi in RA?

Save

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

A step change towards self-empowerment for people living with SLE

Save

In my focus group consisting of people living with SLE and their carers, one of the keys issues raised by them was pertaining to poor reliable information about their condition. At the 2023 EULAR Congress in Milan, I learned about the wide scale dissemination and international launch of Lupus100.org project.

New treatment for Takayasu’s arteritis?

Save

Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.

Zoster protection for JAK inhibitor patients appears achievable

Save

One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.

ANCA-associated vasculitis: beyond therapy with rituximab?

Save

Following the success of Phase 3 randomised controlled trials of non-renal and renal vasculitis, therapy with rituximab has tremendously improved the outcomes of AAV patients. However, some patients are unable to taper their glucocorticoids during rituximab therapy while others appear to be refractory to therapy, particularly those with EGPA. Hence, what are other current or future approaches beyond rituximab?

Methotrexate - an old trusted friend who deserves better

Save

Methotrexate (MTX) has been used as the anchor drug for the treatment of RA and PsA for many years. Despite our long experience with the use of MTX, one area that has remained uncertain is its effect on male fertility. There is now increasing evidence that cessation of MTX in males prior to trying conceive is not necessary.

EULAR 2023 – Day 4 Report

Save

Day 4 was a half day closeout to the EULAR 2023 Congress.

Clinically suspect arthralgias: justified or artefact?

Save

Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.

Are T cells the missing link in pre-clinical RA?

Save

T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. 

Targeted therapies in Sjogren’s syndrome: are we close?

Save

There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.